Welcome to our dedicated page for Champions Oncolo SEC filings (Ticker: CSBR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
R&D milestones, collaboration revenue splits, and non-cash stock-based compensation crowd every Champions Oncology filing. If hunting through 200+ pages to track pipeline progress feels daunting, our AI-powered platform turns that complexity into clarity. StockTitan instantly converts dense SEC jargon into plain-English takeaways—perfect whether you need the latest Champions Oncology insider trading Form 4 transactions or want its Tumorgraft™ revenue breakout without decoding footnotes.
All core documents are here the moment they hit EDGAR. Skim an AI summary of the Champions Oncology annual report 10-K simplified, drill into a Champions Oncology quarterly earnings report 10-Q filing, or set alerts for every Champions Oncology Form 4 insider transactions real-time. Curious about sudden leadership changes? The next Champions Oncology 8-K material events explained will appear with context, showing how a new study read-out might shift revenue guidance.
Use cases our users rely on:
- Compare quarter-over-quarter R&D spend in seconds using Champions Oncology earnings report filing analysis.
- Monitor Champions Oncology executive stock transactions Form 4 before pivotal trial updates.
- Review the Champions Oncology proxy statement executive compensation to evaluate pay vs. performance.
- Save hours understanding Champions Oncology SEC documents with AI rather than parsing scientific appendices yourself.
No more manual searches—just comprehensive coverage, real-time updates, and expert insights that make Champions Oncology SEC filings explained simply.
Champions Oncology (CSBR) reported results from its October 16, 2025 Annual Meeting. All seven director nominees were elected for one-year terms. The strongest director support was for Scott R. Tobin with 9,722,734 votes for.
Stockholders ratified the appointment of EisnerAmper LLP as independent auditor with 10,659,115 votes for. The non-binding advisory vote on executive compensation was approved with 9,720,681 votes for. Broker non-votes totaled 931,779 for proposals requiring them.
Champions Oncology, Inc. (CSBR) filed a Definitive Proxy Statement reporting governance, executive and compensation matters for the 2025 Annual Meeting. As of the record date of August 22, 2025, there were 13,788,421 shares outstanding and the meeting will be held at the company headquarters in Hackensack, New Jersey.
The filing discloses board composition and committee activity: the board has five independent and two non-independent directors, the board met two times during fiscal 2025, the Audit Committee (three independent members) met four times and identified Scott Tobin as the audit committee financial expert. The filing notes related-party consulting fees to a director who beneficially owned ~6.0% of shares, the unexpected death of President Brady Davis in October 2024, and that Robert Brainin will transition into a non-independent CEO role, necessitating committee membership changes. The Audit Committee recommends ratification of EisnerAmper LLP as auditor and the proxy includes a non-binding advisory vote on executive compensation.
FAQ
What is the current stock price of Champions Oncolo (CSBR)?
What is the market cap of Champions Oncolo (CSBR)?
